I’m not surprised they’re reticent! Look up Collins paper in Nature a few weeks ago – brilliant stats assessment of IP-Mass Spec to measure amyloid in PET scans and CSF samples And it’s a very accuratealternative to CSF sampling I do wonder if it’s commercially viable thought (I don’t know enough about IP-MS) <<<AD Risk […]
Thank god for Statisticians – I hate it when clinicians refer to single cases At least there is a big follow up survey And this isn’t rocket science either! <<<DIET>>>
Now this is fascinating – Apple trying to match medical records with subjects on smartphones Would this mean we could do the ultimate in virtual trials Recruit patients from iPhone database, import history data, order and provide medication electronically, prompt patients to take meds and to record ePRO data and even record automically vital signs. […]
I know we’re in the business of making and selling drugs to patients but this is worrying Rosanna O’Connor’s, Public Health England, review will be interesting <<<Hooked>>>
This time it’s Takeda’s turn with pioglitazone (repurposing diabetic treatment) in Phase III <<<AD Failure>>>
Interestingly researchers think the brain potential rewiring may just be turned off with age Valproate an epilepsy drug might help in stroke >>>STROKE<<<
Has your data had this sort of non normal distribution look (as in depression example) Worth considering Robust regression and Bootstrapping and not just ignoring outliers 🙂 <<<NEW METHODS>>>
Just shows you the value of ‘weight of evidence’ ie numbers of subjects >>>Depression Meta Analysis<<<
By popular demand we will restart the blog commenting on interesting daily news items We’ll start with a bit of a catch up – posting interesting items from the last few months 🙂
Now this is what I call a useful app 🙂 <<<Ultrasound>>>